Post-Marketing Surveillance for Crohn's Disease Patients Treated With STELARA
Latest Information Update: 07 Aug 2024
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms K-STAR; STELARA CD PMS
- Sponsors Janssen
- 30 Mar 2022 Status changed from recruiting to completed.
- 08 Dec 2021 Planned primary completion date changed from 30 Nov 2021 to 31 Jan 2022.
- 07 Jun 2021 Planned End Date changed from 31 Dec 2021 to 31 Jan 2022.